DEXCOM INC: directors' dealings · United States · SEC (Form 4)

About DEXCOM INC

DexCom, Inc. is a leading medical technology company focused on continuous glucose monitoring (CGM) for people living with diabetes. The company is listed in the United States on the NASDAQ market under the ticker DXCM. Founded in 1999, DexCom has built a strong position in glucose biosensing and has become one of the best-known names in CGM. Its headquarters are in California, United States, and its business model centers on the design, manufacturing, and commercialization of glucose sensors, transmitters, and companion software that deliver real-time glucose data and digital health integration. ([investors.dexcom.com](https://investors.dexcom.com/news/news-details/2026/Dexcom-Reports-Preliminary-Unaudited-Results-for-the-Fourth-Quarter-and-Fiscal-Year-2025-and-Initial-2026-Outlook/default.aspx?utm_source=openai)) Commercially, DexCom derives most of its revenue from CGM systems sold to diabetes patients, with the Dexcom G7 serving as its flagship offering. The company addresses both insulin-treated patients and a broader, expanding user base as CGM adoption increases. DexCom’s competitive standing is supported by its brand recognition, measurement accuracy, and deep integration with connected-care ecosystems. That combination has helped it remain one of the most visible and influential players in the diabetes technology segment, competing with other established leaders in glucose monitoring and automated diabetes care. ([investors.dexcom.com](https://investors.dexcom.com/news/news-details/2026/Dexcom-Reports-Preliminary-Unaudited-Results-for-the-Fourth-Quarter-and-Fiscal-Year-2025-and-Initial-2026-Outlook/default.aspx?utm_source=openai)) From a geographic perspective, DexCom has an international footprint. It sells in the United States and continues expanding outside the U.S., supported by a growing commercial and regulatory infrastructure. For investors in French-speaking markets, that international diversification is important because it reduces reliance on a single market and supports the company’s long-term growth profile. DexCom has also emphasized broader product access through pharmacy channels and specialized distribution routes, which can improve adoption and convenience for patients. ([investors.dexcom.com](https://investors.dexcom.com/news/news-details/2026/Dexcom-Reports-Preliminary-Unaudited-Results-for-the-Fourth-Quarter-and-Fiscal-Year-2025-and-Initial-2026-Outlook/default.aspx?utm_source=openai)) Recent developments are important to the investment case. DexCom released preliminary full-year 2025 results and initial 2026 guidance, followed by first-quarter 2026 financial results. The company also announced governance enhancements ahead of its 2026 Investor Day and a leadership transition with Jake Leach becoming President and Chief Executive Officer. On the product side, the Dexcom G7 15 Day CGM System began shipping to pharmacies in early January 2026, extending the company’s product range and commercial reach. Overall, DexCom remains a growth-oriented name in Health & Pharma, tied to CGM adoption, product innovation, and competition in the U.S. NASDAQ-listed medical device market. ([investors.dexcom.com](https://investors.dexcom.com/news/news-details/2026/Dexcom-Reports-Preliminary-Unaudited-Results-for-the-Fourth-Quarter-and-Fiscal-Year-2025-and-Initial-2026-Outlook/default.aspx?utm_source=openai))